An interventional study of Intravitreal injection of bevacizumab and Intravitreal injection of ranibizumab (0.5 mg per dose) in Retinal Vein Occlusion and Macular Edema, sponsored by Barnes Retina Institute. Completed at 1 site in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-27.
Sponsored by Barnes Retina Institute · Not applicable, Interventional, and Treatment
Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in treating macular edema resulting from retinal vein occlusion (RVO). In the eye, the two most widely used anti-VEGF agents are ranibizumab and bevacizumab. Only ranibizumab has been FDA-approved for the treatment of macular edema from RVO, however bevacizumab has been used off-label by many ophthalmologists with good success. Furthermore, the cost of bevacizumab is less than one-tenth the cost of ranibizumab. Here the investigators conduct a six month randomized, prospective interventional trial comparing the effectiveness of ranibizumab with bevacizumab in the treatment of macular edema from RVO. Primary outcome measures are change in central retinal thickness. Secondary measures are change in visual acuity from baseline and change in angiographic properties of macular lesions from baseline after treatment.
841 studies on the registry are indexed under Macular Edema; 56 are open to participants now.
This study's planned enrollment of 150 is above the median of 50 across 619 interventional studies indexed under Macular Edema.
Browse Macular Edema studies →Barnes Retina Institute is the lead sponsor of 11 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Intravitreal injection of bevacizumab
Drug: Intravitreal injection of ranibizumab (0.5 mg per dose)
1.25 mg per dose, delivered monthly by intravitreal injection for six months
0.5 mg per dose, delivered monthly by intravitreal injection for six months
change in central retinal thickness
central thickness is measured using optical coherence tomography (OCT)
Time frame: six months compared to baseline
change in best-corrected Snellen visual acuity
best-corrected Snellen visual acuity (BCVA) is the best visual acuity measured using a standard Snellen eye chart at 20 feet between (1) uncorrected vision, (2) vision with current eyeglasses or (3) pinholed visual acuity.
Time frame: six months compared to baseline
change in fluorescein angiogram
fluorescein angiograms will measure area of peripheral nonperfusion. This will be interpreted by a designated physician at each testing center.
Time frame: six months compared to baseline
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Barnes Retina Institute